Predictors of High-Risk and Ultra High-Risk Multiple Myeloma from the Australia &amp; New Zealand Myeloma and Related Diseases Registry (MRDR)

Melissa Ng; Cameron Wellard; Diva Baggio; Elizabeth S. Moore; Emma-Jane Furphy; Hayley Beer; Zoe McQuilten; Joy Ho; Hang Quach; Bradley Augustson; Rajeev Rajagopal; Simon J. Harrison; Andrew Spencer; Amit Khot

doi:10.1016/s2152-2650(25)03866-2

Related publications

Article2025

No benefit from daratumumab, bortezomib and dexamethasone (D‐Vd) in real‐world patients with functional high‐risk multiple myeloma: A report from the Myeloma and Related Diseases Registry

Sueh‐li Lim, Cameron Wellard, Rajeev Rajagopal, Simon J. Harrison, Amit Khot, Hang Quach, P. Joy Ho, Elizabeth S. Moore, Erica M. Wood, Andrew Spencer

Chapter in a book2013

‘There’s gold in them thar students!’ Australia and New Zealand in the global market

Gaby Ramia, Simon Marginson, Erlenawati Sawir

Chapter in a book2013

‘There's gold in them thar students!’ Australia and New Zealand in the global market

Gaby Ramia, Simon Marginson, Erlenawati Sawir

Article2020

Resilience achieved via multiple compensating subsystems: The immediate impacts of COVID-19 control measures on the agri-food systems of Australia and New Zealand

Val Snow, Daniel Rodrı́guez, Robyn Dynes, William Kaye‐Blake, Thilak Mallawaarachchi, S. M. Zydenbos, Lei Cong, Irena Obadovic, R.H. Agnew, Nicole Amery, Lindsay W. Bell, Cristy Benson, Peter W. Clinton, M. Fernanda Dreccer, Andrew Dunningham, Madeleine Gleeson, Matthew Tom Harrison, Alice Hayward, Dean Holzworth, Paul Johnstone, Holger Meinke, Neena Mitter, ,

Article2023

P931: ISATUXIMAB IN RELAPSED MULTIPLE MYELOMA PATIENTS WITH ULTRA-HIGH-RISK CYTOGENETICS: ICARIA-MM AND IKEMA SUBGROUP ANALYSIS

Philippe Moreau, Aurore Perrot, Meletios A Dimopoulos, Thomas G. Martin, Thierry Façon, Marcelo Capra, Meral Beksaç, Nicole M. Armstrong, Franck Dubin, Sandrine Macé, Marie‐Laure Risse, Christina Tekle, Zandra Klippel, Paul G. Richardson

Predictors of High-Risk and Ultra High-Risk Multiple Myeloma from the Australia & New Zealand Myeloma and Related Diseases Registry (MRDR)

Discussion(0)

Related publications

No benefit from daratumumab, bortezomib and dexamethasone (D‐Vd) in real‐world patients with functional high‐risk multiple myeloma: A report from the Myeloma and Related Diseases Registry

‘There’s gold in them thar students!’ Australia and New Zealand in the global market

‘There's gold in them thar students!’ Australia and New Zealand in the global market

Resilience achieved via multiple compensating subsystems: The immediate impacts of COVID-19 control measures on the agri-food systems of Australia and New Zealand

P931: ISATUXIMAB IN RELAPSED MULTIPLE MYELOMA PATIENTS WITH ULTRA-HIGH-RISK CYTOGENETICS: ICARIA-MM AND IKEMA SUBGROUP ANALYSIS

Predictors of High-Risk and Ultra High-Risk Multiple Myeloma from the Australia &amp; New Zealand Myeloma and Related Diseases Registry (MRDR)

Discussion(0)

Related publications

No benefit from daratumumab, bortezomib and dexamethasone (D‐Vd) in real‐world patients with functional high‐risk multiple myeloma: A report from the Myeloma and Related Diseases Registry

‘There’s gold in them thar students!’ Australia and New Zealand in the global market

‘There's gold in them thar students!’ Australia and New Zealand in the global market

Resilience achieved via multiple compensating subsystems: The immediate impacts of COVID-19 control measures on the agri-food systems of Australia and New Zealand

P931: ISATUXIMAB IN RELAPSED MULTIPLE MYELOMA PATIENTS WITH ULTRA-HIGH-RISK CYTOGENETICS: ICARIA-MM AND IKEMA SUBGROUP ANALYSIS

Predictors of High-Risk and Ultra High-Risk Multiple Myeloma from the Australia & New Zealand Myeloma and Related Diseases Registry (MRDR)